二代测序揭示多原发肺癌的基因组与临床意义
本研究对40例拟诊多原发肺癌(MPLC)的手术患者行二代测序,大部分病例突变谱与临床病理诊断一致,但7例(17.5%)检出共享突变提示转移性疾病,且与总生存期显著缩短相关(p < 0.05)。结果提示基因测序可能比传统组织病理评估更准确地进行诊断和预后判断。
要点
- 二代测序可识别拟诊MPLC中共享突变,提示实际为转移性疾病。
- 7例(17.5%)检出共享突变者总生存期显著缩短(p < 0.05)。
- 基因测序可能优于传统病理,助力MPLC诊断与预后判断。
核心结论
- 基因测序技术可能是比传统组织病理评估更准确的诊断和预后工具,用于疑似MPLC患者可更好地指导管理和预测结局。
研究设计与样本
- 对甲醛固定石蜡包埋肿瘤组织提取DNA和RNA,在Ion Torrent Personal Genome Machine系统测序,共40例符合纳入标准。
- 以总生存期和无病生存期评估患者结局。
主要发现
- 多数病例突变谱与临床病理诊断一致。
- 7例(17.5%)检出共享突变,提示转移性疾病。
- 共享突变与总生存期显著缩短相关(p < 0.05)。
临床怎么用
- 对拟诊MPLC患者可考虑二代测序辅助鉴别多原发与转移,共享突变提示转移且预后较差。
局限性
- 样本量较小(40例),为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Marked variations in survival rates have brought into question whether standard clinicopathologic classification should be applied to patients presenting with multiple primary lung cancers (MPLCs). This study investigated the genetic profiles of MPLCs in a cohort of patients using next-generation sequencing and correlated results to clinicopathologic data and patient outcome. METHODS: Patients treated surgically with curative intent for two putative primaries of similar histopathology from January 2000 to December 2019 at St Vincent's Hospital Melbourne. DNA and RNA was extracted from formalin-fixed, paraffin-embedded tumor tissue and sequenced on an Ion Torrent Personal Genome Machine system. Patient outcome was determined by overall survival and disease-free survival. RESULTS: A total of 40 cases fulfilled the inclusion criteria. Mutational profiling was concordant with clinicopathologic diagnosis in most cases; however, seven cases (17.5%) revealed shared mutations suggesting metastatic disease and this was associated with a substantial reduction in overall survival (p < 0.05). CONCLUSIONS: Our results suggest that gene sequencing technologies are potentially a more accurate diagnostic and prognostic tool compared with traditional histopathologic evaluation in patients presenting with suspected MPLCs, which could better guide management and predict outcomes.
引用
- Goodwin D, Rathi V, Conron M, et al. Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing. J Thorac Oncol. 2021. PMID: 33845213. doi:10.1016/j.jtho.2021.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。